Presenting and best-corrected bilateral visual impairment (VI) and blindness are uncommon among Singaporeans, according to a new study. Important risk factors include the Malay ethnicity and advanced age and cataracts.
A recent study by investigators from the Chinese University of Hong Kong (CUHK) showed that low-concentration atropine eye drops could reduce myopia progression in school children by up to nearly 70 percent.
Ranibizumab-related improvements in diabetic retinopathy (DR) severity continue in >70 percent of patients in the open-label extension (OLE) of the RIDE and RISE studies after switching from ranibizumab monthly to an individualized ranibizumab 0.5 mg pro re nata (PRN) dosing regimen.
High-dose cyclosporine A (CsA) cationic emulsion (CE) is well tolerated and effective in improving keratitis, symptoms and quality of life (QOL) in patients with severe vernal keratoconjunctivitis (VKC), according to a phase III study.
Parafoveal flow and vessel density (VD) are significantly reduced in individuals with early cognitive impairment and may serve as early biomarkers for Alzheimer’s disease (AD), according to a recent study.
Adding rescue photodynamic therapy (rPDT) to treatment with the anti-VEGF agent aflibercept intravitreally did not provide additional benefit for patients with polypoidal choroidal vasculopathy (PCV), a type of neovascular age-related macular degeneration (nAMD), according to the PLANET study, suggesting that aflibercept monotherapy sufficed for these patients.
Once-daily dosing of the Rho kinase inhibitor netarsudil is not inferior to twice-daily timolol in terms of lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, while having tolerable adverse events, according to the results of the phase III ROCKET-4 trial.